Status:
RECRUITING
Hepatocellular Carcinoma Identification Using Delta-HLD
Lead Sponsor:
Epiliquid Holding, Inc
Conditions:
Hepato Cellular Carcinoma (HCC)
Eligibility:
All Genders
18-75 years
Brief Summary
HIDE (Hepatocellular Carcinoma Identification via Delta-HLD) is a proof-of-concept case-control study designed to evaluate the performance of delta-HLD, Epiliquid's proprietary liquid biopsy technolog...
Detailed Description
This observational case-control study aims to validate a set of methylation-based biomarkers for HCC detection using delta-HLD technology, which combines enzymatic pre-treatment and multiplexed PCR de...
Eligibility Criteria
Inclusion
- Histologically confirmed HCC (cases) or clinically confirmed liver cirrhosis without HCC (controls)
- Willing and able to provide informed consent
- Available paired plasma and liver tissue sample
Exclusion
- Other active cancers
- Prior liver transplantation
- Known hereditary cancer syndromes
- Recent chemotherapy or antiviral treatment (\<3 months)
Key Trial Info
Start Date :
May 18 2023
Trial Type :
OBSERVATIONAL
Allocation :
ESTIMATED
End Date :
December 1 2026
Estimated Enrollment :
200 Patients enrolled
Trial Details
Trial ID
NCT07148310
Start Date
May 18 2023
End Date
December 1 2026
Last Update
September 9 2025
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
Epiliquid
Mendoza, Argentina, 5500